ARS Pharmaceuticals (SPRY) Net Cash Flow (QoQ) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.82% |
| Dec 31, 2025 | -327.52% |
| Sep 30, 2025 | -31.34% |
| Jun 30, 2025 | 206.60% |
| Mar 31, 2025 | -198.15% |
| Dec 31, 2024 | 268.20% |
| Sep 30, 2024 | 115.64% |
| Jun 30, 2024 | -29.50% |
| Mar 31, 2024 | -243.36% |
| Dec 31, 2023 | 117.85% |
| Sep 30, 2023 | -287.72% |
| Jun 30, 2023 | 125.40% |
| Mar 31, 2023 | -170.82% |
| Dec 31, 2022 | 2,482.99% |
| Sep 30, 2022 | 4.61% |
| Jun 30, 2022 | 2.99% |
| Mar 31, 2022 | -106.47% |
| Dec 31, 2021 | 305.75% |
| Sep 30, 2021 | -306.65% |
| Jun 30, 2021 | -17.41% |
| Mar 31, 2021 | -105.07% |
| Dec 31, 2020 | 117.51% |
| Sep 30, 2020 | 1,630.18% |
| Jun 30, 2020 | -52.50% |